<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Reactive oxygen and nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) have recently been considered to be involved in the cardiovascular complications of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, as NO is thought to lose its beneficial physiological effects in the presence of oxygen radicals </plain></SENT>
<SENT sid="1" pm="."><plain>For this reason, we tested the effects of l-arginine (ARG) and <z:chebi fb="0" ids="28939">N-acetylcysteine</z:chebi> (NAC) administration in increasing NO bioavailability by reducing free radical formation </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A double-blind study was performed on 24 male patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> divided into two groups of 12 patients that randomly received either an oral supplementation of placebo or NAC + ARG for 6 months </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The NAC + ARG treatment caused a reduction of both systolic (P &lt; 0.05) and diastolic (P &lt; 0.05) mean arterial blood pressure, total cholesterol (P &lt; 0.01), <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> (P &lt; 0.005), oxidized <z:chebi fb="15" ids="39026">LDL</z:chebi> (P &lt; 0.05), high-sensitive C-reactive protein (P &lt; 0.05), intracellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (P &lt; 0.05), vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (P &lt; 0.01), nitrotyrosine (P &lt; 0.01), fibrinogen (P &lt; 0.01), and plasminogen activator inhibitor-1 (P &lt; 0.05), and an improvement of the intima-media thickness during endothelial postischemic vasodilation (P &lt; 0.02) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> increased (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>No changes in other parameters studied were observed </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: NAC + ARG administration seems to be a potential well-tolerated antiatherogenic therapy because it improves endothelial function in hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by improving NO bioavailability via reduction of <z:mp ids='MP_0003674'>oxidative stress</z:mp> and increase of NO production </plain></SENT>
<SENT sid="7" pm="."><plain>Our study's results give prominence to its potential use in primary and secondary cardiovascular prevention in these patients </plain></SENT>
</text></document>